Management of CLL and the Role of Minimal Residual Disease
MAY 12th, 2021 - 6-7PM Eastern
Virtual Zoom
Presented by Dr. Matthew Davids, MD, MMSc
Associate Director of the CLL Center
Dana-Farber Cancer Institute
Objectives:
Examine the data supporting MRD as a prognostic marker
Highlight the increasing relevance of MRD as a response assessment tool in the context of novel therapies
Explore practical questions related to the use of MRD, such as how to define "undetectable" MRD
Present the features of different resting methodologies
Discuss the clinical situations and patient types in which MRD may be used to inform clinical management
Comentários